| Dr Shamsunder P Samant, MD | |
|
1777 W Yosemite Ave, Manteca, CA 95337-5130 | |
| (209) 476-2000 | |
| Not Available |
| Full Name | Dr Shamsunder P Samant |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 1777 W Yosemite Ave, Manteca, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699716779 | NPI | - | NPPES |
| 00A325410 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A32541 (California) | Primary |
| Entity Name | American Current Care Of California A Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750573622 PECOS PAC ID: 5799854303 Enrollment ID: O20080522000420 |
News Archive
Researchers at Hospital for Special Surgery have launched a pilot study to see how a drug that treats several related autoimmune disorders affects the skeleton.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor, and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.
Biocell Center announced today its further commitment to working with maternal-fetal-medicine doctors by attending the Society for Maternal-Fetal Medicine's (SMFM) annual meeting.
Gap-toothed youngsters may not be the only ones who are a little sore when they leave the orthodontist's office. While they sport tight braces on their teeth, their doctors may be nursing tight, aching backs, according to a study from the University of Alberta.
MAP Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The Company had previously anticipated initiating a second pivotal efficacy study in the first quarter of 2010.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shamsunder P Samant, MD 1777 W Yosemite Ave, Manteca, CA 95337-5130 Ph: () - | Dr Shamsunder P Samant, MD 1777 W Yosemite Ave, Manteca, CA 95337-5130 Ph: (209) 476-2000 |
News Archive
Researchers at Hospital for Special Surgery have launched a pilot study to see how a drug that treats several related autoimmune disorders affects the skeleton.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor, and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.
Biocell Center announced today its further commitment to working with maternal-fetal-medicine doctors by attending the Society for Maternal-Fetal Medicine's (SMFM) annual meeting.
Gap-toothed youngsters may not be the only ones who are a little sore when they leave the orthodontist's office. While they sport tight braces on their teeth, their doctors may be nursing tight, aching backs, according to a study from the University of Alberta.
MAP Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The Company had previously anticipated initiating a second pivotal efficacy study in the first quarter of 2010.
› Verified 7 days ago
Jasleen Kaur Dhaliwal, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1205 E North St, Manteca, CA 95336 Phone: 951-973-2033 | |
Kanwal S. Gill, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1721 W Yosemite Ave, Manteca, CA 95337 Phone: 209-476-2000 | |
Kenneth C. Moy, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1721 W Yosemite Ave, Manteca, CA 95337 Phone: 209-476-2000 | |
Max William Miller, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1721 W Yosemite Ave, Manteca, CA 95337 Phone: 209-476-2000 | |
Dr. Amanda L Perez, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1777 W Yosemite Ave, Manteca, CA 95337 Phone: 209-825-3555 | |
Dr. John B Woodbury, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1205 E North St, Manteca, CA 95336 Phone: 209-239-8301 | |
Yasmin E. Emery, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1721 W Yosemite Ave, Manteca, CA 95337 Phone: 209-476-2000 |